Edition I · Reader questions
Twelve questions, answered from the literature.
The questions that came up most often in the search-intent corpus, answered with citations and without opinion.
What is the so-called Wolverine peptide blend?
It is a co-administered combination of two research peptides: BPC-157 (a synthetic 15-amino-acid peptide derived from a sequence in human gastric juice) and TB-500 (a synthetic fragment of the 43-amino-acid endogenous peptide thymosin beta-4, carrying the LKKTETQ actin-binding motif). The two are dosed together as a co-formulation; they do not form a single fused chemical entity. The "Wolverine" nickname is online folklore — borrowed from a separate pop-culture intellectual-property universe — that became attached to the blend in late-2010s message-board lore. The vendor research-vial ratios reported online are most commonly 5 mg : 5 mg or 5 mg : 10 mg per vial; no consensus dose exists because there is no FDA-approved combination product [16][18].
What does online literature say about combining BPC-157 and TB-500?
The online discussion typically argues that the two peptides target non-overlapping mechanisms — BPC-157 on vascular and connective-tissue pathways (VEGFR2/Akt/eNOS, growth-hormone-receptor up-regulation) and TB-500 on cytoskeletal remodeling and cell migration (G-actin sequestration, integrin-linked kinase) — and that additive effects are therefore plausible. Independent mechanistic literature acknowledges the non-overlap and the plausibility, but is explicit that no controlled in-vivo study has directly tested the blend versus either peptide alone [18]. The synergy claim is a mechanistic inference, not a measured outcome.
Is the blend FDA-approved or otherwise legal for human use?
Neither BPC-157 nor TB-500 is approved by the U.S. Food and Drug Administration for any human indication, and the combination has no regulatory status as a product. In September 2023 the FDA placed both compounds on its Category 2 list of bulk drug substances of safety concern, effectively prohibiting 503A and 503B compounding pharmacies from producing them. The regulatory landscape has continued to evolve and may differ from these snapshots in any given year.
Is TB-500 banned by WADA? Is BPC-157 banned too?
TB-500 is explicitly prohibited at all times by the World Anti-Doping Agency under category S2 (growth factors and growth-factor modulators); thymosin-β4 and its derivatives are listed by name. BPC-157 has been listed by WADA as a non-approved substance under category S0 since 2022. Athletes subject to WADA testing should treat the blend as prohibited; multi-year sanctions have been issued for TB-500 use in competition.
What is the difference between TB-500 and full-length thymosin beta-4?
TB-500 is a synthetic fragment of the larger 43-amino-acid endogenous peptide thymosin beta-4 (Tβ4). The fragment carries the LKKTETQ motif that binds G-actin, but it is not the full peptide. This distinction is consequential when reading the literature, because most of the published "TB-500" research actually used the full-length Tβ4 — including the cardiac papers in Nature [9][10], the rat embolic-stroke paper [11], the dermal wound-healing work [12], the hair-follicle papers [13], and both the Phase 2 dry-eye trial [15] and the Phase III neurotrophic-keratopathy trial [14], all of which used Tβ4 (RGN-259). Inferences from those papers to the TB-500 fragment are mechanistic rather than direct.
What are the most-cited research doses for BPC-157 and TB-500?
For BPC-157 in rodent models, the value that recurs across the Sikiric-lab program is 10 μg/kg intraperitoneal, once daily — used in the Achilles tendon-to-bone paper [1], the medial collateral ligament paper [2], the muscle-crush paper [3], and the ischemic-colitis paper [6]. Topical and oral protocols in the ligament paper used 1.0 μg in cream and 0.16 μg/mL in drinking water respectively [2]. For full-length Tβ4 in the rat embolic-stroke model, the dose was 6 mg/kg intraperitoneal, repeated every three days for four doses [11]; in cardiac progenitor work the dose was 150 μg per mouse [10]. In human ophthalmic trials the formulation was a 0.1% topical solution dosed five to six times daily [14][15]. There is no published systemic human dose. See /dosage for the full reading.
Has any controlled study tested the BPC-157 + TB-500 blend itself?
No. The literature includes mechanistic syntheses arguing that the two peptides target non-overlapping pathways [18], but no controlled in-vivo study has been published that compares the blend against either peptide as monotherapy. This is the most important caveat for anyone evaluating online claims about the stack.
Why is it nicknamed the Wolverine stack?
The nickname is community folklore from online forums and podcast asides, attached to the blend because both component peptides have been reported in preclinical models to accelerate tissue repair. The name borrows from a pop-culture character in a separate intellectual-property universe and has no clinical, regulatory, or pharmacological standing. This publication uses the literal descriptor "BPC-157 + TB-500 blend" or "regenerative peptide stack" in body copy and reserves the nickname for moments where its search relevance earns a mention.
What 2024–2025 reviews of BPC-157 should I read first?
Four recent reviews are worth opening directly. The 2025 scoping review by McGuire and colleagues in Current Reviews in Musculoskeletal Medicine catalogued 35 preclinical studies and one clinical study and concluded that BPC-157 should be considered investigational [16]. A 2025 literature and patent review by Jozwiak and colleagues in Pharmaceuticals catalogued the pleiotropic preclinical effects and the patent landscape [17]; a published comment-and-reply exchange between Jozwiak and the Sikiric group in the same journal clarified that BPC-157's angiogenic and nitric-oxide modulation is context-dependent [18]. A 2025 systematic review in HSS Journal concluded that off-label orthopaedic-sports-medicine use is outpacing the supporting human evidence and called for formal randomized trials [19].
How long do BPC-157 and TB-500 stay in the bloodstream?
BPC-157's plasma half-life in preclinical work is reported as under 30 minutes, with hepatic metabolism and renal clearance [16]. Thymosin beta-4 is also short-lived in circulation. The short plasma residence of both peptides is cited across the literature as a key limitation for any translational dosing claim and is one of the reasons the published rodent protocols use daily or every-three-day dosing rather than a single administration.
Where do open-access full-text papers on BPC-157 and Tβ4 live online?
PubMed Central (PMC) hosts open-access full-text versions of several of the most-cited papers — including the BPC-157 vascular paper in Scientific Reports [4], the BPC-157 growth-hormone-receptor paper in Molecules [5], the rat embolic-stroke Tβ4 paper in Neuroscience [11], the Phase III neurotrophic-keratopathy trial in IJMS [14], and the 2025 scoping review in Current Reviews in Musculoskeletal Medicine [16]. The MDPI-hosted patent and literature reviews [17][18] are also openly accessible. The /references page links directly to the PMC or publisher landing page for each citation.
Is this site a clinic, pharmacy, or telehealth service?
No. Online Wolverine is an independent online publication that summarizes the peer-reviewed research literature on the BPC-157 + TB-500 blend. The publisher does not employ clinicians, does not provide medical advice, does not manufacture, sell, or distribute any product, and is not affiliated with any vendor or manufacturer. The word "online" in the domain refers to internet-accessible research literature — a reading room online — and is not a representation that the publisher operates a transactional service. See /about for the full editorial framing.